Neus Llarch

797 total citations
23 papers, 518 citations indexed

About

Neus Llarch is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Neus Llarch has authored 23 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 11 papers in Epidemiology and 7 papers in Oncology. Recurrent topics in Neus Llarch's work include Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Liver Disease Diagnosis and Treatment (8 papers) and Liver Disease and Transplantation (3 papers). Neus Llarch is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Liver Disease Diagnosis and Treatment (8 papers) and Liver Disease and Transplantation (3 papers). Neus Llarch collaborates with scholars based in Spain, United States and Canada. Neus Llarch's co-authors include María Reig, Jordi Bruix, Alejandro Forner, Anna Darnell, Jordi Rimola, José Ríos, Ferràn Torres, Carmen Ayuso, Carlos Rodríguez de Lope and Marco Sanduzzi‐Zamparelli and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Journal of Hepatology.

In The Last Decade

Neus Llarch

19 papers receiving 514 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neus Llarch Spain 9 440 201 137 124 87 23 518
Guoliang Shao China 9 375 0.9× 134 0.7× 152 1.1× 155 1.3× 86 1.0× 34 553
Diyang Xie China 8 436 1.0× 215 1.1× 113 0.8× 150 1.2× 150 1.7× 10 632
Vikki Tang China 8 564 1.3× 311 1.5× 89 0.6× 183 1.5× 109 1.3× 20 711
Yong Le China 10 464 1.1× 136 0.7× 216 1.6× 131 1.1× 128 1.5× 11 652
Lianghe Lu China 17 365 0.8× 144 0.7× 92 0.7× 240 1.9× 155 1.8× 41 634
Shao‐Liang Zhu China 11 276 0.6× 147 0.7× 75 0.5× 48 0.4× 61 0.7× 18 354
C. Della Corte Italy 11 264 0.6× 205 1.0× 61 0.4× 66 0.5× 44 0.5× 22 433
Quan Bao China 10 284 0.6× 55 0.3× 92 0.7× 201 1.6× 80 0.9× 36 469
Ji‐Zhen Lu China 12 453 1.0× 170 0.8× 83 0.6× 93 0.8× 89 1.0× 24 517

Countries citing papers authored by Neus Llarch

Since Specialization
Citations

This map shows the geographic impact of Neus Llarch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neus Llarch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neus Llarch more than expected).

Fields of papers citing papers by Neus Llarch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neus Llarch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neus Llarch. The network helps show where Neus Llarch may publish in the future.

Co-authorship network of co-authors of Neus Llarch

This figure shows the co-authorship network connecting the top 25 collaborators of Neus Llarch. A scholar is included among the top collaborators of Neus Llarch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neus Llarch. Neus Llarch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sanduzzi‐Zamparelli, Marco, Andrés Castaño‐García, Neus Llarch, et al.. (2025). Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes. European Journal of Cancer. 221. 115404–115404.
2.
Corominas, Josep, Neus Llarch, Marco Sanduzzi‐Zamparelli, et al.. (2025). Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages. Frontiers in Immunology. 16. 1611365–1611365.
3.
Mauro, Ezequiel, Marco Sanduzzi‐Zamparelli, Raquel García Sevila, et al.. (2024). Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies. Cancers. 16(17). 3059–3059. 5 indexed citations
4.
Muñoz, Sergio, Víctor Sapena, Ángeles García‐Criado, et al.. (2023). Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction. Cancers. 15(13). 3269–3269. 3 indexed citations
5.
6.
Llarch, Neus, Ángeles García‐Criado, Joana Ferrer, et al.. (2023). Implication of patients experience in the liver cancer multidisciplinary approach. Journal of Hepatology. 78. S497–S498.
7.
Matilla, Ana, José Luis Lledó, Marı́a Varela, et al.. (2022). Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. Journal of Clinical Oncology. 40(4_suppl). 428–428. 6 indexed citations
8.
Muñoz, Sergio, et al.. (2021). Current pharmacological treatment of hepatocellular carcinoma. Current Opinion in Pharmacology. 60. 141–148. 16 indexed citations
9.
Corominas, Josep, Víctor Sapena, Marco Sanduzzi‐Zamparelli, et al.. (2021). Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers. 13(3). 426–426. 7 indexed citations
10.
Díaz‐González, Álvaro, Víctor Sapena, Loreto Boix, et al.. (2021). Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs. United European Gastroenterology Journal. 9(6). 655–661. 1 indexed citations
11.
Rimola, Jordi, Anna Darnell, Ernest Belmonte, et al.. (2020). Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. European Radiology. 30(12). 6694–6701. 10 indexed citations
12.
Díaz‐González, Álvaro, Víctor Sapena, Loreto Boix, et al.. (2020). Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. Liver International. 40(10). 2476–2488. 9 indexed citations
13.
Rimola, Jordi, Alejandro Forner, Víctor Sapena, et al.. (2019). Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. European Radiology. 30(1). 186–194. 24 indexed citations
14.
Díaz‐González, Álvaro, Marco Sanduzzi‐Zamparelli, Víctor Sapena, et al.. (2019). Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology & Therapeutics. 49(5). 482–491. 34 indexed citations
15.
Ayuso, Carmen, Alejandro Forner, Anna Darnell, et al.. (2019). Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis. Liver International. 39(7). 1281–1291. 16 indexed citations
16.
Sapena, Víctor, Álvaro Díaz‐González, Anna Darnell, et al.. (2018). Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients. Journal of Hepatology. 68. S205–S206. 1 indexed citations
17.
Reig, María, Loreto Boix, Ferràn Torres, et al.. (2018). Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism. Journal of Hepatology. 68. S197–S197. 3 indexed citations
18.
Reig, María, Ferràn Torres, Carlos Rodríguez de Lope, et al.. (2014). Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Journal of Hepatology. 61(2). 318–324. 180 indexed citations
19.
Reig, María, Carlos Rodríguez de Lope, Neus Llarch, et al.. (2013). 267 DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC). Journal of Hepatology. 58. S113–S113. 2 indexed citations
20.
Reig, María, Jordi Rimola, Ferràn Torres, et al.. (2013). Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. Hepatology. 58(6). 2023–2031. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guoliang Shao Breakdown of academic impact, for papers by Diyang Xie Breakdown of academic impact, for papers by Vikki Tang Breakdown of academic impact, for papers by Yong Le Breakdown of academic impact, for papers by Lianghe Lu Breakdown of academic impact, for papers by Shao‐Liang Zhu Breakdown of academic impact, for papers by C. Della Corte Breakdown of academic impact, for papers by Quan Bao Breakdown of academic impact, for papers by Ji‐Zhen Lu
Rankless by CCL
2026